[Central effect of various new carbamide and succinimide derivatives of benzoxazolone-2].
D000818:Animals; D000927:Anticonvulsants; D001583:Benzoxazoles / Q000494:pharmacology* / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects*; D002219:Carbamates / Q000494:pharmacology* / Q000627:therapeutic use; D002492:Central Nervous System Depressants; D055598:Chemical Phenomena; D002621:Chemistry; D004353:Drug Evaluation, Preclinical; D005260:Female; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009043:Motor Activity / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains; D012640:Seizures / Q000188:drug therapy; D012890:Sleep / Q000187:drug effects; D013388:Succinimides / Q000494:pharmacology* / Q000627:therapeutic use
D000927:Anticonvulsants; D001583:Benzoxazoles; D002219:Carbamates; D002492:Central Nervous System Depressants; D013388:Succinimides
Ośrodkowe działanie nowych pochodnych karbamidowych i sukcynimidowych szeregu benzoksazolonu-2.